Stay Informed on Corporate Sustainability

Author: Archie Villaflores

Innovation, operational excellence, and workforce development continue to accelerate the pharmaceutical and life sciences sector. Organisations that combine technical expertise, strategic vision, and collaborative approaches are setting benchmarks for global impact and sustainable growth. In reflection on last year’s landmark success, ‘Viatris Little Island wins Pharma Project of the Year – Large at Pharma Industry Awards 2025’ highlights the precision and resilience required to deliver complex engineering projects in live production environments. That achievement reinforces how large-scale operational excellence can shape standards for high-impact pharmaceutical initiatives as the 2026 awards cycle approaches. Moreover, ‘SGS’s Expanding Role in Biopharma Quality, Safety, and Scientific Assurance Across Global Network’ illustrates how integrated scientific and regulatory expertise underpins global biopharma innovation. By supporting quality, safety, and compliance across diverse programmes, SGS is enabling companies to accelerate advanced therapies with confidence. Meanwhile, ‘UCC and BioPharmaChem Skillnet bring the future of biopharmaceuticals to learners’ reflects the growing importance of workforce development in emerging technologies. Providing accessible, advanced training ensures that the sector has the skills needed to meet next-generation medicine challenges. These stories underscore how operational leadership, scientific excellence, and talent development are shaping the future of global life sciences.

Author: Jed Nykolle Harme

Celebrated for its excellence last year, Viatris Little Island was named Pharma Project of the Year – Large at the Pharma Industry Awards 2025, setting a benchmark for complex pharma projects as the 2026 awards cycle approaches.

Author: Jed Nykolle Harme

SGS details how its global scientific and regulatory expertise supports quality and safety in advanced biopharma therapies, from development to commercialisation.

Author: Jed Nykolle Harme

As biopharmaceutical innovation accelerates, UCC and BioPharmaChem Skillnet open registrations for the 2026 Certificate in Introduction to Biopharmaceuticals and Advanced Personalised Therapies.

Author: Inquirer.net

Philippine-based Zen LifeSciences is establishing operations in Tarlac’s Luisita Industrial Park Special Economic Zone. The project includes FDA-certified biopharmaceutical production, generating jobs and boosting the country’s pharmaceutical manufacturing sector.

Author: Pharmaceutical Technology

Pfizer has secured a $530m (€445m) vaccine licensing deal with US-based Novavax, centred on its proprietary Matrix-M adjuvant. The agreement underscores corporate partnerships and vaccine innovation in the US life sciences sector.

Author: Euractiv

Ireland has finalised two framework agreements with pharmaceutical manufacturers to accelerate access to new medicines and strengthen supply chains. The deals set reimbursement timelines and aim to enhance Ireland’s competitiveness in the global life sciences sector.

Author: Jed Nykolle Harme

The pharma and life sciences sector continues to evolve through a careful balance of innovation, regulation and human capital, with confidence shaped by long-term thinking rather than short-term gains. This edition brings together perspectives that reflect how leadership, capability and skills development reinforces the sector’s resilience. Credited for redefining standards over the past year, ‘Celtic Biotech wins Biotech Company of the Year at Pharma Industry Awards 2025’ stands as a marker of excellence achieved through scientific focus and organisational discipline. That recognition sets a strong reference point as expectations build towards the 2026 awards, where sustained impact and strategic clarity will remain under close scrutiny. Alongside this, ‘Build Scalable Scientific Teams with SGS Insourcing’ highlights how flexible workforce models are becoming integral to operational confidence, reflecting a broader shift towards adaptability as a competitive advantage in complex regulatory environments. Meanwhile, ‘BioPharmaChem Skillnet Launches Foundational Programme for Aspiring Pharmaceutical Manufacturing Professionals’ underscores the importance of structured learning pathways in securing future capability. Talent development is increasingly viewed as a strategic investment rather than a supporting function. These stories offer readers a lens on how excellence, people and preparation are shaping the next chapter of pharma and life sciences.

Author: Jed Nykolle Harme

Celebrated for its forward-thinking strategies last year, Celtic Biotech was named Biotech Company of the Year at the Pharma Industry Awards 2025, setting a benchmark for innovation in peptide therapies and patient-focused research as attention turns to the 2026 awards cycle.

Author: thepharmaletter

Spanish pharmaceutical company Esteve has agreed to acquire a US-based specialty therapies unit to expand its pharma and life sciences footprint in the United States. The deal strengthens its specialty medicines portfolio and commercial presence.